logo
Plus   Neg
Share
Email

Evotec, Chinook Collaborate To Discover & Develop Medicines For Chronic Kidney Diseases

Evotec SE (EVTCY.PK,EVOTF.PK) and Chinook Therapeutics Inc. (KDNY) said that they have collaborated to focus on the discovery and development of novel precision medicine therapies for patients with chronic kidney diseases or "CKD".

Evotec noted that the collaboration leverages its proprietary PanOmics platform, which combines enhanced throughput proteomics, high throughput transcriptomics and cell imaging with PanHunter, Evotec's unique integrated data analysis platform.

In addition, Chinook will contribute drug discovery and development programs to the collaboration targeting rare kidney diseases such as IgA nephropathy and glomerular diseases.

As per the terms of the deal, Chinook and Evotec will share drug discovery and pre-clinical development responsibilities. Chinook will be responsible for clinical development and commercialization of product candidates developed under the collaboration.

Evotec will receive an undisclosed upfront payment, research funding, and will be eligible to receive progress-dependent milestone payments and tiered royalties on net sales for targets identified through the collaboration.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Inter-American Development Bank and Citi Innovation Labs have successfully completed a proof-of-concept to make cross-border payments from the U.S. to countries in Latin America and the Caribbean, using blockchain and tokenized money. The platform provided full traceability of the transactions, exchange rates, and fees on blockchain. Australian competition regulator said the country's Federal Court found that Google and its Australian arm misled users about the collection and use of personal location data. The data was collected through Android mobile devices between January 2017 and December 2018. This is said to be the world-first enforcement action brought by the Australian Competition and Consumer Commission or ACCC. Morgan Stanley (MS) reported a first-quarter profit that more than doubled from last year, reflecting strong performance across all of its business segment. Net revenues for the quarter grew 61 percent from the previous year. Quarterly adjusted earnings per share beat analysts' estimates.
Follow RTT